HomeLatestQuoin Pharmaceuticals: Leveraging the Value Proposition of Partnerships
Quoin Pharmaceuticals: Leveraging the Value Proposition of Partnerships
February 10, 2022 at 3:52 pm - by Editor Investors Prism
Stock up 6% on better-than-average volume on news of company’s fifth distribution partnership and analyst coverage update
Advancing global support for rare disease treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) is harnessing the power of partnerships to enhance its reach and value. While many smaller biotechs concentrate exclusively on clinical trial results, Quoin’s dual strategy incorporates clinical trials with a focus on creating strong partnerships and the right commercial environment for its rare disease treatments.
Since its foundation in 2018, Quoin has worked to establish connections with foundations that support its patient population, as well as with physicians and leaders in the dermatology field who treat Netherton Syndrome, a rare and devastating genetic skin disease which currently has no treatment or cure. Quoin is positioned to deliver the first FDA-approved treatment for the disease with its lead candidate, QRX003 for Netherton Syndrome, and is targeting regulatory approvals for its pipeline of therapeutics in the United States and Europe in 2024, 2025 and 2026
These strategic relationships are already creating greater awareness about the need for rare disease treatment, addressing reimbursement issues and creating a receptive audience for the company’s therapeutic the moment it is broadly available.
Quoin is committed to developing solutions that improve the quality of life of rare disease patients and their families and has pledged to make its therapeutic available to every patient, everywhere, who is suffering from Netherton Syndrome. To advance the reach of its product ahead of regulatory approvals, Quoin has spent the past four months establishing exclusive distribution agreements with commercial partners in regions around the world. The company’s most recent partnership grants market leader, ER-Kim, exclusive rights to commercialize QRX003 in 15 countries across Central and Eastern Europe.
The company’s commercialization partnerships also include Latin America, the Middle East and North Africa, Russia and CIS (Commonwealth of Independent States) countries, Australia and New Zealand, covering 53 countries in total. Interestingly, a number of these countries have early access programs where therapeutics can be supplied ahead of formal regulatory approval on a named-patient basis. This can spark early revenue generation and real-world results, particularly as Quoin creates its own lean commercial sales and distribution structure for the US and Europe.
Quoin’s ability to leverage the value of partnerships stems from its management team’s extensive experience in successful product launch and commercialization and its dedication to supporting those who have been neglected by other pharmaceutical companies. With a balanced strategy and notable partnerships, Quoin has its sights set clearly on creating long-term value for shareholders while positively changing the lives of underserved patient populations.
“PCG” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PCG” engage in any activities that would require such registrations. “PCG” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PCG” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PCG”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PCG” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.